{"id":"zyrtec-cetirizine","safety":{"commonSideEffects":[{"rate":"2-3%","effect":"Headache"},{"rate":"2-3%","effect":"Somnolence/drowsiness"},{"rate":"1-2%","effect":"Fatigue"},{"rate":"1-2%","effect":"Dry mouth"},{"rate":"1-2%","effect":"Pharyngitis"}]},"_chembl":{"chemblId":"CHEMBL1607273","moleculeType":"Small molecule","molecularWeight":"461.82"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cetirizine competitively inhibits histamine at peripheral H1 receptors, reducing the release and effects of histamine that cause itching, sneezing, rhinorrhea, and urticaria. As a second-generation antihistamine, it is highly selective for H1 receptors and has minimal central nervous system penetration due to its hydrophilic nature and poor blood-brain barrier crossing, resulting in reduced sedation compared to first-generation antihistamines.","oneSentence":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on cells, preventing allergic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:51.065Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal and perennial allergic rhinitis"},{"name":"Chronic urticaria (hives)"}]},"trialDetails":[{"nctId":"NCT00650065","phase":"PHASE1","title":"Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":26},{"nctId":"NCT00649857","phase":"PHASE1","title":"Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-11","conditions":"Healthy","enrollment":18},{"nctId":"NCT04189588","phase":"PHASE2","title":"Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine","status":"COMPLETED","sponsor":"TerSera Therapeutics LLC","startDate":"2020-03-25","conditions":"Oncology Patients Receiving Chemotherapy","enrollment":34},{"nctId":"NCT00794846","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":124},{"nctId":"NCT00794599","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":118},{"nctId":"NCT00794495","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-12","conditions":"Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis","enrollment":122},{"nctId":"NCT00780403","phase":"PHASE4","title":"Multi-Center, Pediatric, Open-Label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec ® 5.0 mg Chewable Tablet Medications (Study P04573) (Completed)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-08","conditions":"Allergies","enrollment":220},{"nctId":"NCT00779116","phase":"PHASE4","title":"Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Allergies","enrollment":217},{"nctId":"NCT03772158","phase":"PHASE1","title":"Cetirizine Chewable Bioequivalence and Food Effect Study","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division","startDate":"2018-12-11","conditions":"Allergy","enrollment":40},{"nctId":"NCT02665754","phase":"PHASE1","title":"Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis","status":"COMPLETED","sponsor":"Gachon University Gil Medical Center","startDate":"2016-07","conditions":"Allergic Rhinitis","enrollment":32},{"nctId":"NCT02932774","phase":"PHASE4","title":"Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Johnson & Johnson Consumer and Personal Products Worldwide","startDate":"2001-03","conditions":"Allergic Rhinitis, Hay Fever, SAR","enrollment":683},{"nctId":"NCT00375713","phase":"PHASE3","title":"Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2005-10","conditions":"Dermatitis, Eczema","enrollment":466},{"nctId":"NCT00240032","phase":"PHASE4","title":"A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2004-10","conditions":"Multiple Sclerosis","enrollment":80},{"nctId":"NCT00863902","phase":"PHASE1","title":"A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Non-fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-08","conditions":"Healthy","enrollment":26},{"nctId":"NCT00864279","phase":"PHASE1","title":"A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2006-08","conditions":"Healthy","enrollment":26},{"nctId":"NCT00776022","phase":"NA","title":"Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2005-04","conditions":"Healthy","enrollment":32},{"nctId":"NCT00776139","phase":"NA","title":"Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2004-10","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1848,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Zyrtec® (cetirizine)","genericName":"Zyrtec® (cetirizine)","companyName":"Organon and Co","companyId":"organon-and-co","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on cells, preventing allergic symptoms. Used for Seasonal and perennial allergic rhinitis, Chronic urticaria (hives).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}